Bristol-Myers licenses potential leukemia therapy developed at Moffitt
January 13, 2020 - ANP Technologies Inc. and Fulgent Pharma LLC, through their partner Moffitt Cancer Center, have successfully licensed the rights to develop a novel targeted therapy in the area of leukemia to Celgene, recently acquired by Bristol-Myers Squibb (NYSE: BMY). Financial terms of the licensing agreement were not disclosed. The partners will work together to develop a new cancer therapy for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), a news release said.